hTERT in cancer chemotherapy: A novel target of histone deacetylase inhibitors

Jun Murakami, Jun-Ichi Asaumi, Hidetsugu Tsujigiwa, Masao Yamada, Susumu Kokeguchi, Hitoshi Nagatsuka, Tatsuo Yamamoto, You Jin Lee

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Chromatin structure plays an important role in the regulation of gene transcription. Chromatin structure can be modified by various post-translational modifications, including histone acetylation, phosphorylation, methylation and ribosylation. Among those modifications, histone acetylation/deacetylation is the most important mechanism for regulating transcription and is regulated by a group of enzymes known as histone acetyltransferases/histone deacetylases (HDACs). Recently, HDAC inhibitors have been shown to be a novel and promising new class of anti-cancer agent that can regulate the transcription of genes by disrupting the balance of acetylation/deacetylation in particular regions of chromatin. A number of HDAC inhibitors are currently in phase I and II clinical trials against a variety of cancers. Although some promising candidates have been identified (e.g., p21WAF1 and c-Myc), the precise molecular targets remain uncertain. In this article, we focus on one of the DNA polymerases, telomerase, as a new candidate molecular target for HDAC inhibitors. Telomerase is composed primarily of the catalytic subunit (hTERT) and the RNA template (hTERC), and its activity correlates with levels of hTERT mRNA. hTERT expression is apparently governed by complicated regulatory pathways. Based on recent studies, the hTERT gene is likely to be targeted by histone acetylation/deacetylation.

Original languageEnglish
Title of host publicationBacterial DNA, DNA Polymerase and DNA Helicases
PublisherNova Science Publishers, Inc.
Pages187-224
Number of pages38
ISBN (Electronic)9781617615733
ISBN (Print)9781607410942
Publication statusPublished - Jan 1 2010

Fingerprint

Acetylation
Histone Deacetylase Inhibitors
Histone Deacetylases
Chemotherapy
Transcription
Histones
Chromatin
Drug Therapy
Genes
Telomerase
Neoplasms
Histone Code
Histone Acetyltransferases
Phase II Clinical Trials
Clinical Trials, Phase I
Phosphorylation
Methylation
DNA-Directed DNA Polymerase
Post Translational Protein Processing
Catalytic Domain

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Murakami, J., Asaumi, J-I., Tsujigiwa, H., Yamada, M., Kokeguchi, S., Nagatsuka, H., ... Lee, Y. J. (2010). hTERT in cancer chemotherapy: A novel target of histone deacetylase inhibitors. In Bacterial DNA, DNA Polymerase and DNA Helicases (pp. 187-224). Nova Science Publishers, Inc..

hTERT in cancer chemotherapy : A novel target of histone deacetylase inhibitors. / Murakami, Jun; Asaumi, Jun-Ichi; Tsujigiwa, Hidetsugu; Yamada, Masao; Kokeguchi, Susumu; Nagatsuka, Hitoshi; Yamamoto, Tatsuo; Lee, You Jin.

Bacterial DNA, DNA Polymerase and DNA Helicases. Nova Science Publishers, Inc., 2010. p. 187-224.

Research output: Chapter in Book/Report/Conference proceedingChapter

Murakami, J, Asaumi, J-I, Tsujigiwa, H, Yamada, M, Kokeguchi, S, Nagatsuka, H, Yamamoto, T & Lee, YJ 2010, hTERT in cancer chemotherapy: A novel target of histone deacetylase inhibitors. in Bacterial DNA, DNA Polymerase and DNA Helicases. Nova Science Publishers, Inc., pp. 187-224.
Murakami J, Asaumi J-I, Tsujigiwa H, Yamada M, Kokeguchi S, Nagatsuka H et al. hTERT in cancer chemotherapy: A novel target of histone deacetylase inhibitors. In Bacterial DNA, DNA Polymerase and DNA Helicases. Nova Science Publishers, Inc. 2010. p. 187-224
Murakami, Jun ; Asaumi, Jun-Ichi ; Tsujigiwa, Hidetsugu ; Yamada, Masao ; Kokeguchi, Susumu ; Nagatsuka, Hitoshi ; Yamamoto, Tatsuo ; Lee, You Jin. / hTERT in cancer chemotherapy : A novel target of histone deacetylase inhibitors. Bacterial DNA, DNA Polymerase and DNA Helicases. Nova Science Publishers, Inc., 2010. pp. 187-224
@inbook{b32ecf63ca034ac6b894b440b8f8991a,
title = "hTERT in cancer chemotherapy: A novel target of histone deacetylase inhibitors",
abstract = "Chromatin structure plays an important role in the regulation of gene transcription. Chromatin structure can be modified by various post-translational modifications, including histone acetylation, phosphorylation, methylation and ribosylation. Among those modifications, histone acetylation/deacetylation is the most important mechanism for regulating transcription and is regulated by a group of enzymes known as histone acetyltransferases/histone deacetylases (HDACs). Recently, HDAC inhibitors have been shown to be a novel and promising new class of anti-cancer agent that can regulate the transcription of genes by disrupting the balance of acetylation/deacetylation in particular regions of chromatin. A number of HDAC inhibitors are currently in phase I and II clinical trials against a variety of cancers. Although some promising candidates have been identified (e.g., p21WAF1 and c-Myc), the precise molecular targets remain uncertain. In this article, we focus on one of the DNA polymerases, telomerase, as a new candidate molecular target for HDAC inhibitors. Telomerase is composed primarily of the catalytic subunit (hTERT) and the RNA template (hTERC), and its activity correlates with levels of hTERT mRNA. hTERT expression is apparently governed by complicated regulatory pathways. Based on recent studies, the hTERT gene is likely to be targeted by histone acetylation/deacetylation.",
author = "Jun Murakami and Jun-Ichi Asaumi and Hidetsugu Tsujigiwa and Masao Yamada and Susumu Kokeguchi and Hitoshi Nagatsuka and Tatsuo Yamamoto and Lee, {You Jin}",
year = "2010",
month = "1",
day = "1",
language = "English",
isbn = "9781607410942",
pages = "187--224",
booktitle = "Bacterial DNA, DNA Polymerase and DNA Helicases",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - hTERT in cancer chemotherapy

T2 - A novel target of histone deacetylase inhibitors

AU - Murakami, Jun

AU - Asaumi, Jun-Ichi

AU - Tsujigiwa, Hidetsugu

AU - Yamada, Masao

AU - Kokeguchi, Susumu

AU - Nagatsuka, Hitoshi

AU - Yamamoto, Tatsuo

AU - Lee, You Jin

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Chromatin structure plays an important role in the regulation of gene transcription. Chromatin structure can be modified by various post-translational modifications, including histone acetylation, phosphorylation, methylation and ribosylation. Among those modifications, histone acetylation/deacetylation is the most important mechanism for regulating transcription and is regulated by a group of enzymes known as histone acetyltransferases/histone deacetylases (HDACs). Recently, HDAC inhibitors have been shown to be a novel and promising new class of anti-cancer agent that can regulate the transcription of genes by disrupting the balance of acetylation/deacetylation in particular regions of chromatin. A number of HDAC inhibitors are currently in phase I and II clinical trials against a variety of cancers. Although some promising candidates have been identified (e.g., p21WAF1 and c-Myc), the precise molecular targets remain uncertain. In this article, we focus on one of the DNA polymerases, telomerase, as a new candidate molecular target for HDAC inhibitors. Telomerase is composed primarily of the catalytic subunit (hTERT) and the RNA template (hTERC), and its activity correlates with levels of hTERT mRNA. hTERT expression is apparently governed by complicated regulatory pathways. Based on recent studies, the hTERT gene is likely to be targeted by histone acetylation/deacetylation.

AB - Chromatin structure plays an important role in the regulation of gene transcription. Chromatin structure can be modified by various post-translational modifications, including histone acetylation, phosphorylation, methylation and ribosylation. Among those modifications, histone acetylation/deacetylation is the most important mechanism for regulating transcription and is regulated by a group of enzymes known as histone acetyltransferases/histone deacetylases (HDACs). Recently, HDAC inhibitors have been shown to be a novel and promising new class of anti-cancer agent that can regulate the transcription of genes by disrupting the balance of acetylation/deacetylation in particular regions of chromatin. A number of HDAC inhibitors are currently in phase I and II clinical trials against a variety of cancers. Although some promising candidates have been identified (e.g., p21WAF1 and c-Myc), the precise molecular targets remain uncertain. In this article, we focus on one of the DNA polymerases, telomerase, as a new candidate molecular target for HDAC inhibitors. Telomerase is composed primarily of the catalytic subunit (hTERT) and the RNA template (hTERC), and its activity correlates with levels of hTERT mRNA. hTERT expression is apparently governed by complicated regulatory pathways. Based on recent studies, the hTERT gene is likely to be targeted by histone acetylation/deacetylation.

UR - http://www.scopus.com/inward/record.url?scp=85049401513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049401513&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85049401513

SN - 9781607410942

SP - 187

EP - 224

BT - Bacterial DNA, DNA Polymerase and DNA Helicases

PB - Nova Science Publishers, Inc.

ER -